Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellulose triacetate: another membrane for continuous renal replacement therapy.

C Ronco1, A Brendolan, P Everard

  • 1Dept of Nephrology, St. Bortolo Hospital, Vicenza, Italy. cronco@goldnet.it

Journal of Nephrology
|September 24, 1999
PubMed
Summary

High-flux cellulose triacetate hemodiafilters demonstrate excellent efficiency and safety for continuous renal replacement therapies in critically ill patients. This modified cellulosic membrane offers a viable alternative to synthetic membranes for improved solute clearance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

sRAGE: a prognostic factor for mortality in end-stage renal disease patients on dialysis.

Journal of biological regulators and homeostatic agents·2019
Same author

The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia.

Leukemia·2017
Same author

Elevated Levels of Procalcitonin and Interleukin-6 are Linked with Postoperative Complications in Cardiac Surgery.

Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society·2017
Same author

Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.

Thrombosis research·2017
Same author

Pathophysiology of the cardio-renal syndromes types 1-5: An uptodate.

Indian heart journal·2017
Same author

The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients.

Critical care (London, England)·2016

Area of Science:

  • Biomaterials Science
  • Nephrology
  • Critical Care Medicine

Background:

  • Technological advancements have driven the development of various renal replacement therapies for acute kidney injury.
  • Continuous therapies like continuous veno-venous hemofiltration and hemodiafiltration are crucial for critically ill patients.
  • Artificial membranes play a vital role in the efficacy of these life-saving treatments.

Purpose of the Study:

  • To evaluate the hydraulic characteristics and solute clearance performance of a high-flux cellulose triacetate hemodiafilter (0.7 m2).
  • To assess the suitability of this modified cellulosic membrane for continuous renal replacement therapies.
  • To compare its efficacy and safety against existing synthetic membranes.

Main Methods:

  • In vitro and in vivo investigations were conducted on a 0.7 m2 high-flux cellulose triacetate hemodiafilter.

Related Experiment Videos

  • Hydraulic properties, including flow dynamics, were analyzed.
  • Solute clearance (urea, creatinine, inulin) and treatment safety were assessed.

    • Main Results:

    • The hemodiafilter's flow dynamics indicate optimal performance with pump-driven veno-venous techniques.
    • Excellent efficiency was observed, with daily urea clearances exceeding 50 liters.
    • High permeability and porosity led to enhanced clearance of larger solutes like creatinine and inulin.
    • No adverse side effects were reported during in vivo treatments.

    Conclusions:

    • Cellulose triacetate hemodiafilters show promising performance for continuous renal replacement therapies.
    • The membrane's characteristics make it a suitable alternative to synthetic membranes.
    • This biomaterial offers effective solute removal and a favorable safety profile in critically ill patients.